Comparison of efficacy and safety of chlorthalidone against hydrochlorthiazide in combiantion with telmisartan in patients with hypertension

Chlorthalidone v/s Hydrochlorthaizide in Combination of Telmisartan in Hypertensive Patients: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/10/046669

Enrollment

Registered

2022-10-20

Start date

Unknown

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Telmisartan and chlorthalidone: Telmisartan 40mg OD ORAL and chlorthalidone 12.5mg OD ORAL DURATION 3 MONTHS Control Intervention1: Telmisartan and hydrochlorthaizide: Telmisartan 40mg

Eligibility

Inclusion criteria

Inclusion criteria: Patient diagnosed with hypertension and SBP between 140 and 159 Mm Hg and DBP between 90 and 99 Mm Hg.

Exclusion criteria

Exclusion criteria: 1. Hypertensive emergency/urgency 2. Known case of other cardiovascular disease. 3. Known case of diabetes mellitus 4. Pregnant women 5. Patient unwilling to participate in trial

Design outcomes

Primary

Measure	Time frame
Change in 24 hours mean systolic and diastolic ambulatory blood pressure (follow up at the end of 3rd month)Timepoint: Baseline and at the end of 3rd month	—

Secondary

Measure	Time frame
1. Comparison of change in mean systolic and diastolic office blood pressure (follow up at the end of 3rd month)Timepoint: Baseline and at the end of 3rd month;2. Comparison of change in night time systolic and diastolic blood pressure (follow up at the end of 3rd month)Timepoint: Baseline and at the end of 3rd month;3. Comparison of serum potassium, sodium, uric acid level (follow up at the end of 3rd month)Timepoint: Baseline and at the end of 3rd month;4.Comparison of renal and liver function (follow up at the end of 3rd month)Timepoint: Baseline and at the end of 3rd month;5.Comparison of lipid profile (follow up at the end of 3rd month)Timepoint: Baseline and at the end of 3rd month;6. HbA1c (baseline and at the end of 3rd month)Timepoint: Baseline and at the end of 3rd month;7.Comparison of any other adverse effect reported by the patientsTimepoint: Baseline and at the end of 3rd month;8.Comparison of rescue medication used to control blood pressureTimepoint: Baseline and at the end of 3rd month	—

Measure

Time frame

1. Comparison of change in mean systolic and diastolic office blood pressure (follow up at the end of 3rd month)Timepoint: Baseline and at the end of 3rd month;2. Comparison of change in night time systolic and diastolic blood pressure (follow up at the end of 3rd month)Timepoint: Baseline and at the end of 3rd month;3. Comparison of serum potassium, sodium, uric acid level (follow up at the end of 3rd month)Timepoint: Baseline and at the end of 3rd month;4.Comparison of renal and liver function (follow up at the end of 3rd month)Timepoint: Baseline and at the end of 3rd month;5.Comparison of lipid profile (follow up at the end of 3rd month)Timepoint: Baseline and at the end of 3rd month;6. HbA1c (baseline and at the end of 3rd month)Timepoint: Baseline and at the end of 3rd month;7.Comparison of any other adverse effect reported by the patientsTimepoint: Baseline and at the end of 3rd month;8.Comparison of rescue medication used to control blood pressureTimepoint: Baseline and at the end of 3rd month

—

Countries

India

Contacts

Public ContactDR JAYKARAN CHARAN

ALL INDIA INSTITUTE OF MEDICAL SCIENCES (AIIMS), JODHPUR

dr.jaykaran78@gmail.com9825219196

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026